– ADMA Biologics
ADMA Biologics, a biopharmaceutical company with operations in New Jersey and Florida, said Monday that recently implemented tariffs on foreign goods and services will have no impact on its operations, citing its fully U.S.-based manufacturing and vertically integrated supply chain.
“ADMA is a U.S.-based company with all manufacturing operations, end-market sales and customer engagements conducted exclusively within the United States,” said Adam Grossman, president and CEO of ADMA Biologics. “Our strategic infrastructure ensures enhanced supply chain robustness, resilience and regulatory compliance.”
The Ramsey-based company emphasized that its end-to-end domestic footprint — including sourcing, production, and distribution — positions it well amid growing national interest in reshoring pharmaceutical supply chains. Grossman added that the company is poised to benefit from federal and private-sector preferences for U.S.-made products and economic incentives tied to domestic production.
ADMA develops, manufactures, and markets specialty biologics used to treat patients with immune deficiencies and those at risk for certain infectious diseases. The company trades on Nasdaq under the ticker ADMA.
